Two new CE Mark approvals

RNS Number : 4578F

Venture Life Group PLC

18 May 2017

 

Venture Life Group plc

("Venture Life" or the "Company")

Two New CE Mark Approvals

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces that two of its new medical device products, Myco-Clear and Rosacalma, have received CE Mark regulatory approval, enabling both products to be marketed and sold as medical devices within the EU.

Myco-Clear is a topical product for the treatment of Onychomicosis (a fungal nail infection).  This condition causes the unsightly discolouration and distortion of finger and toe nails.  It can affect patients as they age and is exacerbated by immunodeficiency disorders, immunomodulating and immunosuppressing drugs and sports activities.  Myco-Clear treats the condition and rapidly improves the appearance of the nail through an easily applied and absorbed once daily topical treatment.

Rosacalma is a complete treatment portfolio for managing the symptoms of Rosacea, an inflammatory skin disease causing facial redness.  Rosacea affects 10% of the general population between 30-50 years of age.  Rosacalma is milder than existing treatments, and is therefore more gentle on the skin and can be used for a much longer period than other usual treatments.  There are three products within the Rosacalma range - a cleanser, a day cream and night serum; all three products were developed in-house and are now ready to be marketed and sold. Both Myco-Clear and Rosacalma will now be presented to potential international distribution partners during 2017, ready for launch in 2018 and beyond.

Jerry Randall, CEO of Venture Life, commented: "The CE Mark approval for Myco-Clear and Rosacalma in Europe is a significant accomplishment that validates these innovative new products.  There is significant unmet need for these products, which we have developed in-house.  2016 was a landmark year for Venture Life which saw 57% revenue growth, further brand development and brand launches.  We are now focused on driving new business through new and existing markets via science, technology and innovation as well as growing our core business portfolio."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

For further information please contact:

Venture Life Group PLC		[phone]
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Northland Capital Partners Limited (Nominated Adviser and Joint Broker)		[phone]
Matthew Johnson / Edward Hutton / Margarita Mitropoulou (Corporate Finance)
Bob Pountney / John Howes (Corporate Broking)
Turner Pope Investments (TPI) Ltd (Joint Broker)		[phone]
James Pope / Ben Turner
Walbrook PR	[e-mail] or + 44 (0) 20 7933 8780
Paul McManus / Anna Dunphy	[phone] / [phone]

About Venture Life (www.venture-life.com) 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. 

 

END

 

 

REASFMFLWFWSEDI